COGNITIVE IMPAIRMENTS AFTER COVID-19 INFECTION
Starchina Yu.A., Vakhnina N.V.
For quotation:
Starchina Yu.A., Vakhnina N.V. Cognitive impairment after COVID-19 infection // Behavioral neurology. 2021. No. 1. pp. 18–26.
DOI 10.46393/2712-9675_2021_1_18-26
Annotation:
In addition to respiratory symptoms, up to 80% of patients with coronavirus infection experience various neurological symptoms, including cognitive impairment. The pathogenesis of the development of cognitive impairment is complex and includes the direct neurotoxic effect of the virus, vascular, dysimmune factors, the consequences of being on mechanical ventilation and the adverse psychological consequences of social isolation, anxiety and depression. Neurometabolic and neuroprotective drugs (Gliatilin) are actively used to treat cognitive impairment after COVID-19 that does not reach the level of dementia.
Journal "Behavioral Neuroscience" No. 1_2021
https://drive.google.com/file/d/1MAiP6dJnIOW75ZCZTJGPSTuzgmfYfGZh/view
Starchina Yu.A., Vakhnina N.V.
For quotation:
Starchina Yu.A., Vakhnina N.V. Cognitive impairment after COVID-19 infection // Behavioral neurology. 2021. No. 1. pp. 18–26.
DOI 10.46393/2712-9675_2021_1_18-26
Annotation:
In addition to respiratory symptoms, up to 80% of patients with coronavirus infection experience various neurological symptoms, including cognitive impairment. The pathogenesis of the development of cognitive impairment is complex and includes the direct neurotoxic effect of the virus, vascular, dysimmune factors, the consequences of being on mechanical ventilation and the adverse psychological consequences of social isolation, anxiety and depression. Neurometabolic and neuroprotective drugs (Gliatilin) are actively used to treat cognitive impairment after COVID-19 that does not reach the level of dementia.
Journal "Behavioral Neuroscience" No. 1_2021
https://drive.google.com/file/d/1MAiP6dJnIOW75ZCZTJGPSTuzgmfYfGZh/view
